Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:523019rdf:typepubmed:Citationlld:pubmed
pubmed-article:523019lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:523019pubmed:issue11lld:pubmed
pubmed-article:523019pubmed:dateCreated1980-3-17lld:pubmed
pubmed-article:523019pubmed:abstractTextFor the development of the DES carcinoma syndrome, two different mechanisms may be assumed. 1. Indirect effect via teratogenesis: squamous cell carcinoma develops from adenosis vaginae with the assistance of cofactors (Fig. 6). Till now, a conversion of adenosis to clear cell carcinoma has never been observed (Hilgers, 1977). Adenosis is probably a precancerous lesion only for squamous cell carcinoma. 2. Transplacental terato-oncogenesis: clear cell carcinoma as a mesonephric carcinoma develops from persisting wolffian ducts with a latent period of 15 to 20 years. DES here acts only as a promoter by way of the transplacental teratogenic mechanism, thus as a terato-co-carcinogenic factor (Fig. 6).lld:pubmed
pubmed-article:523019pubmed:languageenglld:pubmed
pubmed-article:523019pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:523019pubmed:citationSubsetIMlld:pubmed
pubmed-article:523019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:523019pubmed:statusMEDLINElld:pubmed
pubmed-article:523019pubmed:monthNovlld:pubmed
pubmed-article:523019pubmed:issn0029-7828lld:pubmed
pubmed-article:523019pubmed:authorpubmed-author:HillemannsH...lld:pubmed
pubmed-article:523019pubmed:authorpubmed-author:BauknechtTTlld:pubmed
pubmed-article:523019pubmed:authorpubmed-author:SimmerHHlld:pubmed
pubmed-article:523019pubmed:issnTypePrintlld:pubmed
pubmed-article:523019pubmed:volume34lld:pubmed
pubmed-article:523019pubmed:ownerNLMlld:pubmed
pubmed-article:523019pubmed:authorsCompleteYlld:pubmed
pubmed-article:523019pubmed:pagination814-7lld:pubmed
pubmed-article:523019pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-A...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-A...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-P...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-D...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-R...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-F...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-A...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-M...lld:pubmed
pubmed-article:523019pubmed:meshHeadingpubmed-meshheading:523019-A...lld:pubmed
pubmed-article:523019pubmed:year1979lld:pubmed
pubmed-article:523019pubmed:articleTitleThe stilbestrol-adenosis-carcinoma syndrome.lld:pubmed
pubmed-article:523019pubmed:publicationTypeJournal Articlelld:pubmed